关键词: Adalimumab Crohn’s disease Infliximab Tofacitinib Ulcerative colitis Ustekinumab Vedolizumab

Mesh : Colitis, Ulcerative / diagnosis epidemiology therapy Consensus Crohn Disease Humans Inflammatory Bowel Diseases / diagnosis epidemiology therapy United Arab Emirates / epidemiology

来  源:   DOI:10.3748/wjg.v26.i43.6710   PDF(Pubmed)

Abstract:
Ulcerative colitis and Crohn\'s disease are the main entities of inflammatory bowel disease characterized by chronic remittent inflammation of the gastrointestinal tract. The incidence and prevalence are on the rise worldwide, and the heterogeneity between patients and within individuals over time is striking. The progressive advance in our understanding of the etiopathogenesis coupled with an unprecedented increase in therapeutic options have changed the management towards evidence-based interventions by clinicians with patients. This guideline was stimulated and supported by the Emirates Gastroenterology and Hepatology Society following a systematic review and a Delphi consensus process that provided evidence- and expert opinion-based recommendations. Comprehensive up-to-date guidance is provided regarding diagnosis, evaluation of disease severity, appropriate and timely use of different investigations, choice of appropriate therapy for induction and remission phase according to disease severity, and management of main complications.
摘要:
溃疡性结肠炎和克罗恩病是以胃肠道慢性缓解性炎症为特征的炎症性肠病的主要实体。发病率和患病率在全球范围内呈上升趋势,随着时间的推移,患者之间和个体内部的异质性是惊人的。我们对病因认识的进步以及治疗选择的空前增加,已经改变了临床医生对患者进行循证干预的管理。本指南受到阿联酋胃肠病学和肝病学会的鼓励和支持,经过系统评价和Delphi共识过程,提供了基于证据和专家意见的建议。提供有关诊断的全面最新指导,疾病严重程度的评估,适当和及时地使用不同的调查,根据疾病严重程度选择适当的诱导和缓解期治疗,以及主要并发症的处理。
公众号